DE69532673D1 - Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen - Google Patents

Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen

Info

Publication number
DE69532673D1
DE69532673D1 DE69532673T DE69532673T DE69532673D1 DE 69532673 D1 DE69532673 D1 DE 69532673D1 DE 69532673 T DE69532673 T DE 69532673T DE 69532673 T DE69532673 T DE 69532673T DE 69532673 D1 DE69532673 D1 DE 69532673D1
Authority
DE
Germany
Prior art keywords
mum
microspheres
neuroactive
microcapsules
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69532673T
Other languages
English (en)
Other versions
DE69532673T2 (de
Inventor
Amanda Mcrae-Mcfarland
B Dahlstrom
L Dillon
R Tice
W Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MCRAE MCFARLAND AMANDA
SOUTHERN RES INST BIRMINGHAM
Southern Research Institute
Original Assignee
MCRAE MCFARLAND AMANDA
SOUTHERN RES INST BIRMINGHAM
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MCRAE MCFARLAND AMANDA, SOUTHERN RES INST BIRMINGHAM, Southern Research Institute filed Critical MCRAE MCFARLAND AMANDA
Publication of DE69532673D1 publication Critical patent/DE69532673D1/de
Application granted granted Critical
Publication of DE69532673T2 publication Critical patent/DE69532673T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
DE69532673T 1994-06-29 1995-06-28 Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen Expired - Fee Related DE69532673T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/268,177 US6517859B1 (en) 1990-05-16 1994-06-29 Microcapsules for administration of neuroactive agents
US268177 1994-06-29
PCT/US1995/008123 WO1996000537A1 (en) 1994-06-29 1995-06-28 Microcapsules for administration of neuroactive agents

Publications (2)

Publication Number Publication Date
DE69532673D1 true DE69532673D1 (de) 2004-04-15
DE69532673T2 DE69532673T2 (de) 2005-02-17

Family

ID=23021810

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532673T Expired - Fee Related DE69532673T2 (de) 1994-06-29 1995-06-28 Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen

Country Status (8)

Country Link
US (2) US6517859B1 (de)
EP (1) EP0767634B1 (de)
JP (1) JPH10506373A (de)
AT (1) ATE261278T1 (de)
DE (1) DE69532673T2 (de)
DK (1) DK0767634T3 (de)
ES (1) ES2217281T3 (de)
WO (1) WO1996000537A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US7247374B2 (en) * 2002-06-12 2007-07-24 Traptek Llc Encapsulated active particles and methods for making and using the same
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006097725A2 (en) * 2005-03-15 2006-09-21 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
EP1929073A4 (de) * 2005-09-27 2010-03-10 Amunix Inc Proteinöse arzneimittel und ihre verwendung
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
EP2021405B1 (de) * 2006-05-09 2014-04-09 Cocona, Inc. Aktive partikelerweiterte membran und herstellungs- und verwendungsverfahren dafür
WO2009019534A2 (en) 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008063557A2 (en) * 2006-11-16 2008-05-29 Gregory Haggquist Exothermic-enhanced articles and methods for making the same
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
EP2131919A4 (de) * 2007-04-02 2010-10-20 Georgia Tech Res Inst Implantierbre vorrichtung zur kommunikation mit biologischem gewebe
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2342356A4 (de) 2008-09-29 2012-11-21 Univ Ben Gurion Amyloid-beta-peptidasen und verwendungsverfahren dafür
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
CN106519205B (zh) * 2016-10-26 2018-04-10 河南工程学院 一种载药多孔phbv接枝多巴胺微球的制备方法及应用
KR20190110567A (ko) 2017-01-31 2019-09-30 베루 인코퍼레이티드 성선 자극 호르몬-방출 호르몬(GnRH) 길항제의 장기간 방출을 위한 조성물 및 방법
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. PEPTIDE INHIBITORS OF TAU AGGREGATION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS6048923A (ja) 1983-08-25 1985-03-16 Mitsui Toatsu Chem Inc 微小粒子の製造方法
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4882686A (en) * 1987-06-22 1989-11-21 Eastman Kodak Company Printing apparatus with improved data formatting circuitry
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
DE69001672T2 (de) 1989-06-21 1993-12-23 Univ Brown Res Found Neurologisches therapiesystem.
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (de) 1989-07-28 1992-01-15 Debiopharm Sa
JP3187410B2 (ja) 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
EP0528978B1 (de) 1990-05-16 2002-10-16 Southern Research Institute Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums

Also Published As

Publication number Publication date
EP0767634A1 (de) 1997-04-16
US6517859B1 (en) 2003-02-11
JPH10506373A (ja) 1998-06-23
DK0767634T3 (da) 2004-07-19
US20020094347A1 (en) 2002-07-18
ATE261278T1 (de) 2004-03-15
EP0767634B1 (de) 2004-03-10
ES2217281T3 (es) 2004-11-01
EP0767634A4 (de) 1998-09-30
WO1996000537A1 (en) 1996-01-11
DE69532673T2 (de) 2005-02-17
US6565875B2 (en) 2003-05-20

Similar Documents

Publication Publication Date Title
DE69532673D1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
DE69133136D1 (de) Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DE69529054D1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
CA2198245A1 (en) Methods and means for drug administration
MX9603489A (es) Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
MY105073A (en) Transdermal therapeutical system comprising physostigmine as active component and process for the production thereof.
ATE204468T1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
HK1048058A1 (zh) 肝臟選擇性的藥用活性物
BG106106A (en) Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
AU2173400A (en) Method for administering agents to the central nervous system
MXPA02012075A (es) Composicion para mediar el dolor y aparato y metodo para utilizarla.
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
ATE361772T1 (de) Behalter zur iontophoretischen verabreichung von medikamenten mit inerten material-bestandteilen
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
WO2003026489A3 (en) Biopolymer and biopolymer-cell compositions for nerve tissue repair
GB9506796D0 (en) Device
ATE295157T1 (de) Mittel zur transdermalen verabreichung von arzneistoffen
DE69737296D1 (de) Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen
FR2686250B1 (de)
ATE257727T1 (de) Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten
Godlevskii et al. Enhancement of the antiepileptic efficacy of diazepam at electrical stimulation of the cerebellar cortex
DE69803607T2 (de) Zusammensetzungen zur transdermalen und dermalen verabreichung von biologisch wirksamen stoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee